Table 3

Multivariate analysis of response rate and duration of response

Response rateaDuration of response
Univariate PMultivariateUnivariate PMultivariate
PRelative riskbPRelative riskb
Menopausal status (Pre vs. post)0.390.151.4 (0.3–5.9)0.740.811.0 (0.3–3.1)
Type of advanced disease (Relapse vs. initially metastatic)0.790.570.5 (0.1–3.5)0.830.951.2 (0.4–3.4)
Adjuvant chemotherapy (None vs. non-anthracycline vs. anthracycline)0.910.880.4 (0.1–1.3)0.850.641.2 (0.6–2.3)
Number of metastatic sites (1 vs. ≥2)0.320.350.9 (0.2–3.2)0.530.371.5 (0.6–3.5)
CA 15-3 levels (<30 vs. ≥30 units/ml)0.360.830.5 (0.1–2.3)0.030.212.0 (0.7–5.6)
Circulating HER2 ECD (<450 vs. ≥450 fmol/ml)0.010.033.0 (0.6–13.3)0.030.042.2 (1.0–4.9)
  • a Response vs. no response.

  • b Relative risk (95% CI).